AlphAIAlphAI — Financial news for AI agents
yahoo.comSEP 113 min read$CRSP

Set Yourself Up for a Strong 2027: 2 Pharmaceutical Stocks to Buy in September

CRISPR Therapeutics (CRSP) and Viking Therapeutics (VKTX) are highlighted as potential pharmaceutical stocks to buy. CRISPR's Casgevy treatment is expected to generate significant revenue in 2027, with analysts projecting revenue to grow from $40M to $156M. Viking Therapeutics is developing a monthly GLP-1 weight-loss injection and an oral pill, with analysts setting a 12-month price target of $93.11 for VKTX, a 175% increase from its current price.

Original reporting
yahoo.com
Published Sep 11, 2026, 10:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 11, 2026, 10:20 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Set Yourself Up for a Strong 2027: 2 Pharmaceutical Stocks to Buy in September — source image
Source · yahoo.com
Decision brief

The 30-second read

$CRSPNeutralLow
01

Why it matters

Provides no new primary data; serves as a thematic suggestion.

02

Market read

Article may influence interest in biotech equities but lacks actionable new information.

03

What to watch

Regulatory timelines and competitive pressure from larger biotech firms.

Relevance 4/10Novelty 2/10Timing: September 2026 recommendation

Background

The piece is a forward‑looking stock recommendation for two biotech firms.

Company-level read

Ticker impact

$CRSPNeutralMedium confidence
Context

Article discusses CRISPR Therapeutics' pending revenue from Casgevy and projected growth to 2027.

Expected impact

Modest upside if Q2 revenue trends continue.

Evidence & confidence

No new data released; article is forward‑looking.

$VKTXNeutralMedium confidence
Context

Article highlights Viking Therapeutics' GLP‑1 drug VK2735 development and analyst price target.

Expected impact

Limited upside pending trial results.

Evidence & confidence

Article provides opinion, no fresh catalyst.

Market effects

Sector

Highlights potential interest in gene‑editing and GLP‑1 therapeutics.

Regional

US biotech sector focus.

Global

Limited to investors tracking biotech pipelines.

Counterpoint

What could challenge this read

Both companies face significant execution risk; growth may be overstated.

Key entities

  • Company
    CRISPR Therapeutics

    Gene‑editing biotech developing Casgevy.

  • Company
    Viking Therapeutics

    Developer of GLP‑1 weight‑loss drug VK2735.

Read at source← All news

Related articles

SEP 15
$VKTXMedAI 8/10

Viking Therapeutics Advances VK2735 Obesity Drug Into Phase 3 After 15% Weight Loss

Viking Therapeutics (VKTX) is advancing its obesity drug VK2735 into Phase 3 trials after achieving 15% weight loss in Phase 2. The Phase 3 studies will test various dosing schedules and formulations, with a focus on tolerability and weight-loss maintenance. The company aims to leverage data from injectable studies for its oral program, reducing enrollment by about 75%. Viking is also preparing for commercialization, securing manufacturing capacity and supply-chain redundancy.

finance.yahoo.com2 min
SEP 8
$CRSPMedAI 8/10

Why CRISPR Therapeutics Stock Rocked the Market Last Month

CRISPR Therapeutics (CRSP) shares rose 19% in August following its Q2 earnings report. Sales of its blood disorder treatment Casgevy increased 78% to $76M, and the FDA expanded its approval. Revenue reached $10.2M, up from $892K a year ago, with a net loss of $91.5M. Analysts expected lower revenue and a larger loss. The company is developing treatments for hypertension and other disorders.

yahoo.com3 min
SEP 8
$CRSPMedAI 8/10

Where Will CRISPR Therapeutics Stock Be in 5 Years?

CRISPR Therapeutics (CRSP) reported $76M in Q2 2026 revenue from Casgevy, up 78% sequentially and 151% YoY. The company has a strong pipeline, including CTX310 for cardiovascular disease and Zugo-cel for autoimmune diseases. With $2.36B in cash and a $5.4B market cap, CRISPR has financial flexibility to advance multiple programs. Success in these areas could significantly increase its valuation by 2031, though risks remain.

yahoo.com3 min
AUG 30
$CRSPMedAI 8/10

CRISPR Therapeutics (CRSP) Stock May Look Rich Following Fresh CTX310 Data

CRISPR Therapeutics (CRSP) stock is down 52.7% over 5 years, despite recent gains. The company presented Phase 1a data for CTX310, which may boost confidence in its drug pipeline. However, the stock is considered overvalued on market multiples, trading at a P/B of 3.2x, above the biotech industry average. Investors are paying a premium for its pipeline potential, but clinical and regulatory risks remain significant.

simplywall.st3 min
AUG 28
$CRSPMedAI 8/10

CRISPR Therapeutics Presents Phase 1a Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and LDL Lowering at ESC Congress 2026

CRISPR Therapeutics (CRSP) presented Phase 1a data for CTX310® at ESC Congress 2026, showing mean reductions of 79% in ANGPTL3, 48% in triglycerides, and 53% in LDL at the highest dose. The therapy was well tolerated with no serious adverse events. Data was also published in The New England Journal of Medicine. The company is advancing CTX310 in a Phase 1b trial and expects to provide an update in the second half of 2026.

globenewswire.com2 min